Oral Anti-Androgen Alternatives to Spironolactone for Hirsutism and Acne
For women of childbearing age with hirsutism and acne, oral contraceptives (OCPs) are the recommended first-line treatment, with cyproterone acetate (CPA) 2 mg combined with ethinyl estradiol being particularly effective; finasteride 5 mg daily can serve as an alternative antiandrogen, while flutamide should be avoided due to hepatotoxicity risk. 1
Primary Alternative: Oral Contraceptives
The Endocrine Society guidelines clearly prioritize OCPs as first-line therapy for the majority of women with hirsutism 1. This recommendation is based on:
- Efficacy: OCPs reduce free testosterone by increasing sex hormone-binding globulin (SHBG) and suppressing ovarian androgen production
- Safety profile: Similar side effects to placebo in clinical trials
- Dual benefit: Provides contraception while treating hyperandrogenic symptoms
Specific OCP Formulations
OCPs containing antiandrogen progestins are most effective:
Cyproterone acetate (CPA) 2 mg + ethinyl estradiol: Most effective option, showing similar efficacy to other antiandrogens in systematic reviews 1. CPA blocks androgen receptors and inhibits 5α-reductase activity. Note: CPA is not available in the United States.
Drospirenone 3 mg + ethinyl estradiol: FDA-approved for acne in patients ≥14 years 2. However, drospirenone is a weak antiandrogen (3 mg drospirenone ≈ 25 mg spironolactone) 1. A 12-month trial showed similar hirsutism reduction compared to CPA 1.
Other progestins: Dienogest, desogestrel, and chlormadinone acetate have demonstrated antiacne activity 3, though research suggests dienogest may not impact hirsutism 4.
Secondary Alternative: Finasteride
Finasteride 5 mg daily is a reasonable alternative antiandrogen when OCPs are contraindicated or not tolerated 1:
- Mechanism: Inhibits type 2 5α-reductase, reducing conversion of testosterone to dihydrotestosterone (DHT)
- Efficacy: Reduces hirsutism scores by 30-60% 1. Meta-analysis showed no significant differences between finasteride, spironolactone, and flutamide versus placebo 1
- Comparative data: One trial suggested equal efficacy to spironolactone 100 mg, though another found spironolactone more effective with prolonged treatment 1
- Safety: No major adverse effects reported 1
- Dosing: 5 mg daily is standard, though some data suggest 2.5 mg and 5 mg are equally effective 1
Critical caveat: Finasteride is teratogenic and requires strict contraception 1. The guidelines explicitly recommend against antiandrogen monotherapy unless adequate contraception is used 1.
Alternatives to AVOID
Flutamide: Not Recommended
The guidelines explicitly recommend against flutamide therapy 1 despite its efficacy:
- Efficacy: Doses of 250-750 mg/day show similar efficacy to spironolactone 100 mg/day 1
- Major concern: Hepatotoxicity leading to liver failure and death 1
- Risk mitigation: Hepatotoxicity may be dose-related; lower doses (62.5-375 mg/day) showed no hepatotoxicity in some series 1
- Guideline position: Not first-line therapy; if used, employ lowest effective dose with close monitoring 1
Other Non-Recommended Options
- Topical antiandrogens: Limited efficacy, not recommended 1
- Insulin-lowering drugs (metformin, thiazolidinediones): Not recommended for hirsutism treatment 1
- GnRH agonists: Reserved only for severe hyperandrogenemia (e.g., ovarian hyperthecosis) with suboptimal response to OCPs and antiandrogens 1
- Glucocorticoids: Only for nonclassic congenital adrenal hyperplasia with suboptimal response to first-line therapies 1
Treatment Algorithm
For women of childbearing age:
- First-line: Start OCP (preferably CPA-containing if available, or drospirenone-containing)
- Trial duration: Minimum 6 months before changing therapy 1
- If inadequate response after 6 months: Add antiandrogen to OCP 1
- If OCPs contraindicated/not tolerated: Finasteride 5 mg daily with mandatory contraception
- Avoid: Flutamide as routine therapy
For women who cannot or choose not to conceive: Either OCPs or antiandrogens (finasteride preferred over flutamide), with choice based on patient preferences regarding efficacy, side effects, and costs 1.
Important Clinical Considerations
- Contraception is mandatory with all antiandrogen monotherapy due to teratogenic potential 1, 5
- Treatment duration: All pharmacological therapies require at least 6 months before assessing response 1
- Combination therapy: If monotherapy with OCP fails after 6 months, add an antiandrogen rather than switching 1
- Patient counseling: Discuss realistic expectations, as improvement is gradual and requires sustained therapy